Meeting Banner
Abstract #3724

Longitudinal Neurochemical Changes of Riluzole Therapy in Post-Traumatic Stress Disorder

Sam H. Jiang1, David M. Benedek2, Patricia Spangler2, James West2, Catherine L. Dempsey2, Ashley Phares2, Brian Andrews-Shigaki3, Eduardo Coello1, and Alexander P. Lin1
1Center for Clinical Spectroscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States, 2Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 3Office of Naval Research, United States Navy and Marine Corps, Alexandria, VA, United States

Active duty service members and veterans with post-traumatic stress disorder (PTSD) refractory to evidence-based therapy were randomized to receive either riluzole, a glutamate modulator, or placebo adjunctive to selective serotonin reuptake inhibitor therapy over an 8-week period. Subjects underwent 1H brain magnetic resonance spectroscopy scans pre- and post-treatment and were assessed longitudinally for PTSD symptomology using the Clinician-Administered PTSD Scale (CAPS). Subjects were stratified into improved and non-improved groups based on a decrease in CAPS score. Analyses on within- and between-group metabolite differences revealed that riluzole modulated the glutamate-glutamine cycle, improved neural energetics, and may have induced choline-linked neuroprotective inflammation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here